vs
FrontView REIT, Inc.（FVR）与KESTRA MEDICAL TECHNOLOGIES, LTD.（KMTS）财务数据对比。点击上方公司名可切换其他公司
KESTRA MEDICAL TECHNOLOGIES, LTD.的季度营收约是FrontView REIT, Inc.的1.4倍（$22.6M vs $16.5M），FrontView REIT, Inc.净利率更高（-24.9% vs -145.3%，领先120.4%）
Kestra Medical Technologies（KMTS）是一家专注于微创医疗器械研发、生产与商业化的医疗科技企业，核心产品覆盖介入心脏病学与结构性心脏病治疗领域，市场覆盖北美、欧洲及亚太重点区域，服务全球医疗机构与患者。
FVR vs KMTS — 直观对比
营收规模更大
KMTS
是对方的1.4倍
$16.5M
净利率更高
FVR
高出120.4%
-145.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $16.5M | $22.6M |
| 净利润 | $-4.1M | $-32.8M |
| 毛利率 | — | 50.6% |
| 营业利润率 | — | -140.7% |
| 净利率 | -24.9% | -145.3% |
| 营收同比 | — | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.19 | $-0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRKMTS
| Q4 25 | $16.5M | $22.6M | ||
| Q3 25 | $16.8M | $19.4M | ||
| Q2 25 | $17.6M | — | ||
| Q1 25 | $16.2M | — | ||
| Q3 24 | $14.5M | — |
净利润FVRKMTS
| Q4 25 | $-4.1M | $-32.8M | ||
| Q3 25 | $4.0M | $-25.8M | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-833.0K | — | ||
| Q3 24 | $-2.4M | — |
毛利率FVRKMTS
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | 45.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
营业利润率FVRKMTS
| Q4 25 | — | -140.7% | ||
| Q3 25 | — | -149.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
净利率FVRKMTS
| Q4 25 | -24.9% | -145.3% | ||
| Q3 25 | 23.9% | -133.3% | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -5.1% | — | ||
| Q3 24 | -16.7% | — |
每股收益（稀释后）FVRKMTS
| Q4 25 | $-0.19 | $-0.64 | ||
| Q3 25 | $0.19 | $-0.50 | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.06 | — | ||
| Q3 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.5M | $175.4M |
| 总债务越低越好 | $314.3M | — |
| 股东权益账面价值 | $391.2M | $164.1M |
| 总资产 | $854.4M | $246.7M |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资FVRKMTS
| Q4 25 | $13.5M | $175.4M | ||
| Q3 25 | $19.6M | $201.2M | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $3.3M | — | ||
| Q3 24 | — | — |
总债务FVRKMTS
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q3 24 | — | — |
股东权益FVRKMTS
| Q4 25 | $391.2M | $164.1M | ||
| Q3 25 | $385.2M | $184.2M | ||
| Q2 25 | $369.9M | — | ||
| Q1 25 | $324.7M | — | ||
| Q3 24 | $1.0K | — |
总资产FVRKMTS
| Q4 25 | $854.4M | $246.7M | ||
| Q3 25 | $846.8M | $266.3M | ||
| Q2 25 | $856.5M | — | ||
| Q1 25 | $860.8M | — | ||
| Q3 24 | $1.0K | — |
负债/权益比FVRKMTS
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q3 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $42.1M | $-18.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-25.6M |
| 自由现金流率自由现金流/营收 | — | -113.5% |
| 资本支出强度资本支出/营收 | — | 32.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FVRKMTS
| Q4 25 | $42.1M | $-18.3M | ||
| Q3 25 | $8.3M | $-26.3M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $8.1M | — | ||
| Q3 24 | — | — |
自由现金流FVRKMTS
| Q4 25 | — | $-25.6M | ||
| Q3 25 | — | $-34.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
自由现金流率FVRKMTS
| Q4 25 | — | -113.5% | ||
| Q3 25 | — | -177.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
资本支出强度FVRKMTS
| Q4 25 | — | 32.2% | ||
| Q3 25 | — | 42.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
现金转化率FVRKMTS
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
